Clinical Trial Update: Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of a dual CD22/CD19 CAR-T therapy as first-line consolidation for B-cell lymphoma, with the trial currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CD22/CD19 CAR-T therapy

Snippet

Sponsor: Daihong Liu | Conditions: Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING